Drug Trial Radar · NCT06450886
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Jan 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Abcuro, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.
Conditions
- Inclusion Body Myositis (IBM)
Interventions
Ulviprubart (ABC008)Drug
All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center
Phoenix, Arizona
University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center
Irvine, California
Keck Hospital of USC
Los Angeles, California
Yale School of Medicine
New Haven, Connecticut
Neuromuscular Diagnostic Center - Massachusetts General Hospital
Boston, Massachusetts
Brigham and Womens Hospital
Boston, Massachusetts
Hospital for Special Surgery
New York, New York
Duke Neurological Disorders Clinic
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Ohio State University Wexner Medical Center
Columbus, Ohio
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
UPMC Arthritis and Autoimmunity Center, Falk Clinic
Pittsburgh, Pennsylvania
Austin Neuromuscular Center
Austin, Texas
Texas Neurology
Dallas, Texas
Nerve and Muscle Center of Texas
Houston, Texas
Virginia Commonwealth University
Henrico, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Perron Institute for Neurological and Translational Science
Nedlands, Washington, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.